Here’s Why Bristol-Myers Needs a $74 Billion Shot in the Arm

Bookmark
(Bloomberg Opinion) -- Bristol-Myers Squibb Co.’s impending $74 billion acquisition of biotechnology giant Celgene Inc. makes it easy to overlook something as relatively prosaic as the firm’s fourt...
BQ Install

Bloomberg Quint

Add BloombergQuint App to Home screen.